Streetbeat News

Products Services

EXAS

Exact Sciences Corp. (NASDAQ:EXAS) will present data from the ASCEND-2 study at the AACR Annual Meeting 2024, showcasing the effectiveness of its investigational multi-cancer early detection (MCED) blood test. The study, involving over 11,000 participants, demonstrates high detection rates and specificity for aggressive cancers and those without standard screening tests. Additionally, outcomes from the DETECT-A study will be presented, highlighting the potential of MCED tests in revolutionizing cancer screening.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 4:06 pm

AGR

Avangrid, Inc. (NYSE:AGR) and Statkraft have signed a Virtual Power Purchase Agreement (VPPA) for Renewable Energy Certificates (RECs) from Avangrid's Streator Cayuga Ridge South Wind Farm in Illinois. This marks the first U.S. agreement between Avangrid and Statkraft, expanding their partnership beyond Europe. The VPPA aims to support the clean energy transition and manage merchant risk at Avangrid's renewable energy facilities.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 4:03 pm

MRUS

Merus N.V. (NASDAQ:MRUS) presented preclinical data at the AACR Annual Meeting 2024 showing the efficacy of zenocutuzumab (Zeno) in cancer models with high NRG1 expression. The study demonstrated Zeno's anti-tumor activity across multiple tumor types, including significant tumor growth inhibition in 7 out of 28 patient-derived xenograft models. Zeno, a HER2 × HER3 bispecific antibody, also inhibited proliferation in specific gastric and breast cancer cell lines, as well as an NRG1-amplified lung cancer cell line.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 4:03 pm

INKT

MiNK Therapeutics, Inc. (NASDAQ:INKT) announced promising preclinical data for MiNK-215, a novel CAR-iNKT cell therapy targeting colorectal cancer liver metastases, at the AACR Meeting. The therapy showed potent anti-tumor activity in human organoid models, including tumor stroma remodeling, immune activation, and enhanced tumor killing. The results suggest MiNK-215 could overcome limitations of current immunotherapies and work synergistically with other treatments like Agenus' botensilimab and balstilimab.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 4:02 pm

AAPL

JPM

NVDA

Jamie Dimon, CEO of JPMorgan Chase & Co (NYSE:JPM), emphasized the transformative potential of AI, comparing its impact to major technological inventions like electricity. JPMorgan's strong performance, partly attributed to AI, highlights the broader benefits of AI beyond tech stocks. The article also notes positive early trade money flows in NVDA, AMZN, META, TSLA, SPY, and QQQ, with neutral flows in GOOG and MSFT, and negative in AAPL. Additionally, it mentions the buying of Bitcoin ETFs and the performance of gold and oil ETFs, GLD and USO.

Portfolio Pulse from The Arora Report

April 08, 2024 | 4:01 pm

RUN

On CNBC, Sunrun CEO Mary Powell discussed the company's position, trends in the solar sector, and its market share. She highlighted Sunrun's strategic initiatives and its outlook within the evolving solar energy market.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 4:00 pm

AGCO

AGCO Corporation (NYSE:AGCO) announced the launch of PTx, a new precision ag technology brand, combining technologies from Precision Planting and the new joint venture, PTx Trimble. PTx aims to accelerate AGCO's technology transformation, offering retrofit and factory-fit solutions to farmers globally through specialized dealers and OEM partnerships. The initiative is led by Seth Crawford and aims to provide seamless, intelligent, and farmer-centric technologies. The JV with Trimble was completed on April 1, 2024, with Andrew Sunderman named as General Manager of PTx Trimble.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 3:52 pm

GMAB

LLY

NUVB

ProfoundBio Inc. is set to be acquired by Genmab A/S (NASDAQ:GMAB) for $1.8 billion, marking the fourth acquisition of a China-related innovative drugmaker by a foreign company in recent months. This trend reflects the challenges Chinese drugmakers face in becoming profitable due to high development costs and market pressures. ProfoundBio, with its advanced cancer treatment drugs, represents a valuable addition to Genmab's portfolio. Other notable acquisitions include Gracell Biotechnologies by AstraZeneca, SanReno Therapeutics by Novartis, and AnHeart Therapeutics by Nuvation Bio Inc. (NASDAQ:NUVB). Eli Lilly (NYSE:LLY) is also mentioned as a backer of ProfoundBio.

Portfolio Pulse from The Bamboo Works

April 08, 2024 | 3:43 pm

AAPL

GOOGL

META

MSFT

NVDA

QQQ

SPY

TSLA

The Market Clubhouse Morning Memo for April 8th, 2024, provides trading strategies for SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA, based on a proprietary formula. It offers detailed analysis for each, suggesting potential price movements and targets for both bullish and bearish scenarios. The memo also notes that market activity may be quieter due to sparse economic events, with attention on the New York Fed's Survey and Treasury's bill auctions. Additionally, it promotes Market Clubhouse's services, including live daily market analysis and real-time mentorship by a pro trader known as RIPS.

Portfolio Pulse from RIPS

April 08, 2024 | 3:40 pm

BMY

Bristol Myers Squibb (NYSE:BMY) announced positive results from the KRYSTAL-1 study for KRAZATI in combination with cetuximab, showing significant efficacy in treating KRASG12C-mutated colorectal cancer. The study, funded by Mirati Therapeutics, a Bristol Myers Squibb company, will be presented at the AACR annual meeting. The FDA has accepted a supplemental new drug application for this combination, with a PDUFA goal date of June 21, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 3:31 pm